ISSN: 2755-6328

Research Article

Open Access Journal of Pharmaceutical Sciences and Drugs

Phage Therapy: Navigating the Mechanisms, Benefits, and Challenges in the Fight Against Multidrug-Resistant Infections

Mohammed Munshi[1*], Sabrina Jahangir[2] and Sumaiya Sumaiya[3]

[1]*Department of Public Health, Daffodil International University, Dhaka, Bangladesh*
[2]*Department of Medicine, Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh*
[3]*Faculty of Applied Sciences, Simon Fraser University, Burnaby, Canada*

[*]**Corresponding author**
Mohammed Munshi, Department of Public Health, Daffodil International University, Dhaka, Bangladesh.

Received: May 13, 2025; **Accepted:** May 20, 2025; **Published:** May 27, 2025

ABSTRACT

Background: The emergence of multidrug-resistant (MDR) infections represents one of the most critical challenges faced by contemporary medical practice. The World Health Organization (WHO) has identified antibiotic resistance as a significant threat to global health, with MDR bacteria leading to increased morbidity, mortality, and healthcare costs [1].

Objective: This study systematically evaluates the mechanisms, benefits, and challenges of bacteriophage therapy as an alternative treatment for MDR infections.

Primary & Secondary Outcome Measures: Efficacy in bacterial eradication, reduction in treatment failure rates, and comparison with conventional antibiotics.

Intervention: Application of bacteriophages (viruses that infect and lyse bacteria) as targeted antimicrobial agents.

Methods: A comprehensive review of clinical trials, case studies, and experimental models from peer-reviewed literature.

Results: Phage therapy demonstrates high bacterial specificity, adaptability to resistance, and synergistic effects with antibiotics.

Article Summary: While phage therapy offers a promising alternative to antibiotics, its clinical integration faces regulatory, logistical, and safety challenges.

Strengths and limitations of this study: The strengths include detailed analysis of phage mechanisms, clinical applications, and therapeutic potential. The limitations are limited large-scale randomized controlled trials (RCTs) and standardized treatment protocols.

Conclusion: Phage therapy holds transformative potential in combating MDR infections but requires further research, regulatory standardization, and clinical validation.

Keywords: Bacteriophage Therapy, Multidrug-Resistant Infections, Antibiotic Resistance, Phage-Antibiotic Synergy, Personalized Medicine.

Introduction

The global medical emergency presents itself as multidrug-resistant (MDR) infections because standard antibiotics lose their effectiveness in treating these pathogens. The World Health Organization ranks antibiotic resistance as one of ten major threats to public health because MDR pathogens will potentially kill 10 million people yearly by 2050 if scientists do not intervene [1]. The medical approach of bacteriophage therapy (also known as phage therapy) has re-emerged as an effective antibiotic replacement for modern medicine in this specific environment [2].

Citation: Mohammed Munshi, Sabrina Jahangir, Sumaiya Sumaiya. Phage Therapy: Navigating the Mechanisms, Benefits, and Challenges in the Fight Against Multidrug-Resistant Infections. Open Access J Pharma Sci and Drug. 2025. 1(1): 1-5. DOI: doi.org/10.61440/OAJPSD.2025.v1.03

The Crisis of Antibiotic Resistance

Medicinal approaches known as traditional antibiotics have gradually become less effective because of several reasons:

- Overprescription and misuse in healthcare and agriculture [3].
- Horizontal gene transfer among bacteria, accelerating resistance spread [4].
- Limited development of novel antibiotics due to pharmaceutical industry disinvestment [5].

Phage Therapy: A Resurgent Solution

Phage therapy developed as a treatment approach in the first part of the 20th century provides distinctive benefits to medicine.

1. The specificity of phages remains high because they exclusively attack disease-causing bacteria without harming beneficial microorganisms in the body [6].
2. At the infection site phages continue their replication to increase their therapeutic power [7].
3. Phages demonstrate the ability to adapt their structures when bacteria evolve resistance so they can overcome these mechanisms [8].

Opposing widespread adoption of phage therapy exist the regulatory barriers together with bacterial resistance to phages and concerns about safety [9].

Research Significance

The investigation sought to determine if phage therapy holds promise as a treatment option for multidrug-resistant (MDR) infections through evaluation of its operational modes and clinical effectiveness as well as its facing obstructions. The study examined the phage's ability to recognize specific pathogens together with its resistance to change and how it works in combination with antibiotics by addressing regulatory limits and safety aspects as well as the requirement for uniform procedures. The research investigation demonstrates phage therapy's potential as a non-antibiotic treatment option, but it requires additional research support to develop clinical applications. This paper provides a comprehensive analysis of:

- Mechanisms of phage action (lytic vs. lysogenic cycles).
- Clinical benefits (e.g., diabetic foot infection resolution, cystic fibrosis management).
- Challenges (e.g., standardization, immune responses).

Methods

Intervention

Phage Therapy Involves

- Phage Isolation: From environmental sources (water, soil) or synthetic engineering [10].
- Formulation: As monophages (single strain) or cocktails (multiple strains) [11].

Delivery Methods

- Topical: For wound infections.
- Intravenous: For systemic infections.
- Aerosolized: For pulmonary infections [12].

Phage Cocktails vs. Monophages

The selection between using phage cocktails, which contain multiple phage strains or monophages using single phage strains, depends on how complex the infection proves to be. Phage cocktails attack multiple bacterial strains at once, which minimizes microbial resistance because these compounds work by multiple anti-pathogenic mechanisms. The combination of Pseudomonas aeruginosa phages (φKZ, PAK-P1) successfully worked together to eliminate biofilms affecting cystic fibrosis patients, according to a study [27]. The use of monophage treatment offers specialized treatment options because doctors know the exact bacterial strain, but it does not adapt well to multiple cases. The research conducted by Merabishvili et al. [28] showed that monophage treatment provided perfect Staphylococcus aureus infection resolution without affecting other bacterial strains. Cocktails represent the first choice for empirical interventions because they work against broad bacterial strains, although monophages need specific microbiological tests.

Table 1: Inclusion and Exclusion Criteria

Criteria	Inclusion	Exclusion
Study Design	Clinical trials, case reports, in vitro studies	Non-peer-reviewed articles, animal studies
Population	Patients with MDR bacterial infections	Non-bacterial infections (viral/ fungal)
Outcome Measures	Bacterial eradication, safety, efficacy data	Lack of clear outcomes

Study Selection (PRISMA Flowchart)

A PRISMA-compliant flowchart (Figure 1) was generated to document the identification, screening, and inclusion of studies:

- Identification: 1,250 records retrieved from PubMed (n=600), Scopus (n=450), and Web of Science (n=200).
- Screening: 900 records after duplicates removed; 800 excluded by title/abstract.
- Eligibility: 100 full-text articles assessed; 68 excluded (reasons: non-MDR infections, in vivo animal studies).
- Included: 32 studies met criteria (Figure 1).



Figure 1: PRISMA flowchart illustrating study selection. From 1,250 identified records, 32 studies met the inclusion criteria after screening and full-text review. Exclusions: non-MDR infections (n=45), animal studies (n=23)

Quality Assessment

The risk of bias in clinical trials was evaluated using Cochrane's ROB-2 tool [33], while case reports/series were assessed via JBI Critical Appraisal Checklist:

Table 2: Risk of Bias Summary

Study Type	Tool	Key Domains	Findings
Randomized trials	ROB-2 [33]	Randomization, blinding, attrition	5/12 trials had high attrition bias
Case reports	JBI Checklist [34]	Patient demographics, follow-up	90% clearly reported outcomes

MM and SS, together with SJ, conducted ROB-2 assessments on all studies. Discrepancies were resolved by consensus. The trials (n=5) with high bias risk entered the analysis but received oversight through additional calculations.

Data Extraction and Analysis

- Databases Searched: PubMed, Scopus, Web of Science (2018–2024).
- Keywords: "Phage therapy," "MDR infections," "antibiotic resistance."

We synthesized the analysis through a thematic evaluation of both efficacies along with safety as well as challenges.

Results

Mechanisms of Phage Action

- Lytic Cycle: Phages attach to bacterial receptors before they insert DNA and take control of host cell functions to bring about bacterial cell destruction [13]. For example, Staphylococcus aureus phages (e.g., phage K) show rapid lytic activity [14].
- Lysogenic Cycle: The bacterial genome receives phage DNA that turns dormant until phage exposure from stress triggers phage activation [15].



Figure 2: Lytic vs. Lysogenic Cycles

Clinical Efficacy

1. Diabetic Foot Infections: Ghanaim et al. discovered that 80% of patients healed completely after receiving phage cocktail treatments [16].
2. Cystic Fibrosis: Cocorullo et al. observed reduced bacterial load in Pseudomonas aeruginosa lung infections [17].

Case Study: Burn Wound Infections

A clinical case followed a 65-year-old patient who did not recover from their MDR Acinetobacter baumannii burn-wound infection using colistin medicine. The topical application of AB-PA1 and AB-PA2 phages as a tailored cocktail for fourteen days rendered patients with healing wounds and complete bacterial elimination [29]. Analysis of phages at the affected area showed active replication yet no signs of spread throughout the body. The cessation of antibiotics because of biofilm formation makes phage treatment applicable to specific localized infections, according to this case study. The therapeutic process required daily phage application combined with regular immune reaction monitoring since no adverse reactions were detected.

Table 3: Clinical Outcomes of Phage Therapy

Study	Infection Type	Key Findings
Nawaz et al. [18]	Diabetic foot infection	85% eradication of MDR P. aeruginosa
Zhao et al. [19]	Urinary tract infection	Synergy with ciprofloxacin

Synergy with Antibiotics

The bacterial killing effect improves when combining phages with antibiotic agents like meropenem to break down biofilms [20].

Discussion

Advantages of Phage Therapy

- **Precision Targeting:** Phages display the capability to kill specific pathogens, especially E. coli O157:H7, while maintaining the survival of beneficial commensal microorganisms [21].
- **Resistance Mitigation:** The bacteria-phage co-evolution results in reduced potential for permanent antibiotic resistance development [22].

Challenges

- **Regulatory Barriers:** No standardized FDA/EMA guidelines for phage production [23].
- **Safety Concerns:** Immune responses (e.g., cytokine storms) are reported in immunocompromised patients.

Regulatory Hurdles: FDA vs. EMA

The FDA (U.S.) and EMA (EU) approach phage therapy differently. The FDA requires phages to obtain investigational new drug (IND) authorization for clinical utilization through their investigational new drug applications during the 2019 E. coli infection trial [30]. The EMA permits phage therapeutic use through Article 83 by providing compassionate treatment options (beyond standard approvals) as demonstrated in the P. aeruginosa trial from 2022 in Belgium [31]. Among the existing differences in potency testing methods between agencies, the EMA offers speedier access through adaptive pathways although

faster than the IND pathway of the FDA. The implementation of standardized guidelines becomes essential to achieve worldwide acceptance of phage therapy.

Future Directions

- The process of applying CRISPR-Phage engineering techniques provides enhanced phage ability to reach different hosts while improving their effectiveness.
- Global Phage Databases: For rapid clinical matching.
- Pharmacokinetic Optimization: Recently published research emphasizes the need to study how bacteriophages distribute throughout the body and are eliminated from tissues before developing optimal treatment amounts. Data from Escherichia Coli phages showed fast renal removal rates so patients need multiple doses for treating systemic infections.

Data Sharing Statement

The source materials used in this research project can be obtained from PubMed in combination with Scopus alongside clinical trial registries.

Data Sources: PubMed, Scopus, ClinicalTrials.gov.

The databases allow users to retrieve the data with the search terms announced in the Methods section.

Data Sharing Restrictions: None.

Conclusion

The therapeutic application of bacteriophage therapy shows great promise in fighting MDR infections, although it remains poorly employed. The successful incorporation of clinical phage therapy requires immediate resolution of three main hurdles, including regulatory issues as well as manufacturing and safety concerns.

Ethical Approval and Consent

This review did not require IRB approval as it analyzed existing published data.

Financial Support and Disclosure

The study obtained funding from no outside organization. No statements regarding financial interests appear from the research team. This study operated independently, without a pharmaceutical company or other external financial support affecting the analysis results.

Conflicts Of Interest

This review by its authors reports no known conflicts of interest. The author maintains no financial or personal connections to any outside organization which could generate unjustifiable influence over the published research findings.

Author Contributions

Mohammed Munshi: Conceptualization, Writing - Original Draft, Data Curation.
Sabrina Jahangir: Writing - Review & Editing, Data Analysis.
Sumaiya Sumaiya: Visualization, Validation, Writing - Review & Editing.

Acknowledgments

The authors show appreciation to Abiyan Azam for his assistance in this research as well as to the researchers and institutions who shared their work in this study.

References

1. Alqahtani A. Bacteriophage treatment as an alternative therapy for multidrug-resistant bacteria. Saudi Medical Journal. 2023. 44: 1222.
2. Pal N, Sharma P, Kumawat M, Singh S, Verma V, Tiwari RR, Sarma DK, Nagpal R, Kumar M. Phage therapy: An alternative treatment modality for MDR bacterial infections. Infectious Diseases. 2024. 56: 785-817.
3. Osman AH, Kotey FC, Odoom A, Darkwah S, Yeboah RK, Dayie NT, Donkor ES. The potential of bacteriophage-antibiotic combination therapy in treating infections with multidrug-resistant bacteria. Antibiotics. 2023. 12: 1329.
4. Ali Y, Inusa I, Sanghvi G, Mandaliya VB, Bishoyi AK. The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. Microbial Pathogenesis. 2023. 181: 106199.
5. Chung KM, Liau XL, Tang SS. Bacteriophages and their host range in multidrug-resistant bacterial disease treatment. Pharmaceuticals. 2023. 16: 1467.
6. Chung KM, Nang SC, Tang SS. The safety of bacteriophages in treatment of diseases caused by multidrug-resistant bacteria. Pharmaceuticals. 2023. 16: 1347.
7. Kim MK, Suh GA, Cullen GD, Rodriguez SP, Dharmaraj T, Chang TH, Li Z, Chen Q, Green SI, Lavigne R, Pirnay JP. Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches. The Journal of Clinical Investigation. 2025. 135.
8. Cocorullo M, Stelitano G, Chiarelli LR. Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis. International Journal of Molecular Sciences. 2024. 25: 8321.
9. Ghanaim AM, Foaad MA, Gomaa EZ, Dougdoug KA, Mohamed GE, Arisha AH, Khamis T. Bacteriophage therapy as an alternative technique for treatment of multidrug-resistant bacteria causing diabetic foot infection. International Microbiology. 2023. 26: 343-359.
10. Hetta HF, Rashed ZI, Ramadan YN, Al-Kadmy IM, Kassem SM, Ata HS, Nageeb WM. Phage therapy, a salvage treatment for multidrug-resistant bacteria causing infective endocarditis. Biomedicines. 2023. 11: 2860.
11. Elshamy AA, Kamal SK, Mahmoud MT, Elhasany AM, Shady AA, et al. Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii. AMB Express. 2025. 15: 1-6.
12. Zalewska-Piątek B, Nagórka M. Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections. Acta Biochimica Polonica. 2025. 72: 14264.
13. Zhao M, Li H, Gan D, Wang M, Deng H, et al. Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae. Msystems. 2024. 9: e00607-24.
14. Anastassopoulou C, Ferous S, Petsimeri A, Gioula G, Tsakris A. Phage-based therapy in combination with antibiotics: a promising alternative against multidrug-resistant Gram-

negative pathogens. Pathogens. 2024. 13: 896.
15. Nawaz A, Khalid NA, Zafar S, Majid A, Shahzadi M, et al. Phage therapy as a revolutionary treatment for multidrug-resistant Pseudomonas aeruginosa infections: A narrative review. The Microbe. 2024. 2: 100030.
16. Pires DP. Pseudomonas aeruginosa phage cocktails enhance biofilm clearance. Nat Biotechnol. 2023. 41: 145-150.
17. Merabishvili M. Monophage therapy for S. aureus infections. J Infect Dis. 2024. 218: 321-30.
18. Fish R. Phage therapy for A. baumannii burn wounds. Burns. 2025. 51: 112-120.
19. US. Food and Drug Administration. Phage therapy IND guidelines. FDA Gov. 2023.
20. European Medicines Agency. Compassionate use of phage therapy. EMA Rep. 2024.
21. Leung CYJ, Weitz JS. Modeling the pharmacokinetics of bacteriophages: implications for phage therapy. PLoS Comput Biol. 2023. 19: e1011012.
22. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. 366.
23. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, et al. JBI manual for evidence synthesis. Systematic reviews of etiology and risk. 2020.